Global Minimal Residual Disease Testing Market Size To Grow USD 4.38 Billion by 2032 | CAGR of 11.7%
Category: HealthcareGlobal Minimal Residual Disease Testing Market Size To Grow USD 4.38 Billion by 2032
According to a research report published by Spherical Insights & Consulting the Global Minimal Residual Disease (MRD) Testing Market Size is To Grow from USD 1.45 Billion in 2022 to USD 4.38 Billion by 2032, at a Compound Annual Growth Rate (CAGR) of 11.7% during the forecast period.
Get more details on this report -
Browse key industry insights spread across 200 pages with 110 Market data tables and figures & charts from the report on the "Global Minimal Residual Disease (MRD) Testing Market, By Technology (Flow-cytometry, Polymerase Chain Reaction {PCR}, Next Generation Sequencing {NGS}), By Test Type (DNA-based Test, RNA-based Test, Immunological Test), By Application (Lymphoma, Leukemia, Solid Tumors), By End Use (Hospitals, Specialty Clinics, Diagnostic Laboratories, Research & Academic Institutes), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022– 2032." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/minimal-residual-disease-testing-market
The market for diagnostic tests used to detect the presence of cancer cells in patients who have completed therapy is referred to as the global minimal residual disease (MRD) testing market. MRD testing is a very sensitive and specific tool that may detect minute quantities of cancer cells that may remain in a patient's body after treatment. The MRD testing market comprises products and services such as assays, flow cytometers, and other testing equipment, as well as associated services such as sample preparation and analysis. The market serves healthcare practitioners, research institutions, and pharmaceutical firms that use MRD testing for disease monitoring, therapy selection, and clinical trial findings. Furthermore, advances in minimum residual illness detection technologies contribute to advancements in cancer treatment strategies. Furthermore, these minimum residual sickness tests are specially designed to measure treatment effectiveness, aid physicians in verifying and monitoring remissions, and maybe detect an early return of cancer.
The MRD testing market comprises commodities and services such as assays, flow cytometers, and other testing equipment, as well as associated services such as sample preparation and analysis. The market serves healthcare practitioners, research institutions, and pharmaceutical firms that employ MRD testing for disease monitoring, therapy selection, and clinical trial findings. Moreover, breakthroughs in minimum residual sickness diagnosis technology contribute to advancements in cancer treatment tactics. Furthermore, MRD tests, like other diagnostic and therapeutic approaches, are governed by stringent and complicated rules. Depending on the type of test used, there are numerous concerns concerning its effectiveness and appropriateness. Multiparameter flow cytometry investigations, for example, may be difficult to interpret and may overlook some cytogenetic markers. As a result of the combination of tight standards and MRD test restrictions, the industry's development and progress are restricted.
Covid 19 Impacts
The recent COVID-19 epidemic has had a detrimental influence on the revenue of the minimal residual disease testing business. Other disease testing services had been significantly influenced by the profitable demand for COVID-19 testing. The incidence and death rate of COVID-19 was highest during the early period, and persons preferred to avoid any additional treatment or diagnostic treatments at institutions. The risk of infection during a cancer diagnostic test at a point-of-care facility has led to the postponement of the treatment.
The flow-cytometry segment is influencing the market with the largest market share during the forecast period.
The global minimum residual disease testing market is divided into three segments based on technology such as flow cytometry, polymerase chain reaction PCR, and next-generation sequencing NGS. Among these segments, the flow-cytometry segment has the biggest revenue share throughout the predicted period. This is due to flow cytometry's high sensitivity and widespread use in MRD testing. Individual cells are examined using flow cytometry to check if certain protein markers are present on the cell surface. For reliable results, a fresh bone marrow sample is necessary.
The DNA-based Test segment is dominating the largest market share over the forecast period.
The global minimum residual illness testing market is divided into different categories based on the test type such as DNA-based tests, RNA-based tests, and immunological tests. Among these categories, the DNA-based Test segment is expected to dominate the market throughout the projected period due to its high specificity and sensitivity for identifying cancer cells. However, due to advancements in technologies such as next-generation sequencing (NGS) and digital PCR, the RNA-based testing industry was anticipated to grow at the fastest CAGR throughout the projection period.
The lymphoma segment is dominating the market with the largest market share during the forecast period.
The global minimum residual disease testing market is bifurcated into three applications including lymphoma, leukemia, and solid tumors. The lymphoma sector, among them, is predicted to have substantial growth potential throughout the study period due to the rising incidence of lymphoma, which is expected to increase the market in the approaching years. According to the American Cancer Society, about 90,300 Americans will be diagnosed with lymphoma by 2021. This disease load is expected to grow with each passing year. Lymph node swelling in the neck, armpits, or groin is a common symptom of lymphoma.
North America led the market with the largest market share over the forecast period
Get more details on this report -
North America is expected to lead substantial market expansion during the projection due to it is attributed to government-implemented preventative measures to reduce disease progression. Also, because patients and physicians are well aware of the benefits of screening, the United States and Canada are the two largest markets for cancer screening in North America. In addition, many programs in the region are being started to provide MRD testing..
Asia Pacific is predicted to experience strong revenue market growth throughout the forecast period. Japan is likely the largest market in the Asia Pacific due to increased investment in screening and the availability of supporting reimbursement policies. Furthermore, the region has a high prevalence of hematological malignancies, necessitating MRD testing.
Major vendors in Global Minimal Residual Disease Testing Market include Exact Sciences Corporation, GRAIL, LLC, Veracyte, Inc., Natera, Inc., Guardant Health, F. Hoffmann-La Roche Ltd, FOUNDATION MEDICINE, INC., QIAGEN, mdxhealth, Bio-Techneand, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In February 2022, Invitae initiated research to collect real-world data on tailored minimum residual disease testing across different tumor types.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Minimal Residual Disease Testing Market based on the below-mentioned segments:
Global Minimal Residual Disease Testing Market, By Technology
- Flow-cytometry
- Polymerase Chain Reaction {PCR}
- Next Generation Sequencing {NGS}
Global Minimal Residual Disease Testing Market, By Test Type
- DNA-based Test
- RNA-based Test
- Immunological Test
Global Minimal Residual Disease Testing Market, By Application
- Lymphoma
- Leukemia
- Solid Tumors
Global Minimal Residual Disease Testing Market, By End Use
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Research & Academic Institutes
Minimal Residual Disease Testing Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- Uk
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?